key: cord-0725730-yhyeywvc authors: Ho, Kam Sing; Howell, Daniel; Rogers, Linda; Narasimhan, Bharat; Verma, Hannah; Steiger, David title: The Relationship Between Asthma, Eosinophilia, and Outcomes in COVID-19 Infection date: 2021-02-27 journal: Ann Allergy Asthma Immunol DOI: 10.1016/j.anai.2021.02.021 sha: 379d7ec87bfb5d9f5e0920ef369acc35a1a67d32 doc_id: 725730 cord_uid: yhyeywvc BACKGROUND: The impact of asthma diagnosis and asthma endotype on outcomes from COVID-19 infection remains unclear. OBJECTIVE: To describe the association between asthma diagnosis and endotype and clinical outcomes among patients diagnosed with COVID-19 infection. METHODS: Retrospective multicenter cohort study of outpatients and inpatients presenting to six hospitals in the Mount Sinai Health System New York metropolitan region between March 7 th to June 7 th , 2020, with COVID-19 infection, with and without a history of asthma. The primary outcome assessed was in-hospital mortality. Secondary outcomes included hospitalization, intensive care unit (ICU) admission, mechanical ventilation, and hospital length of stay. Outcomes were compared in patients with or without asthma using a multivariate Cox regression model. Outcomes stratified by blood eosinophilia count were also assessed. RESULTS: Of 10,523 patients diagnosed with COVID-19 infection, 4902 patients were hospitalized, and 468 had a diagnosis of asthma (4.4%). When adjusted for COVID-19 disease severity, comorbidities, and concurrent therapies, patients with asthma had a lower mortality [adjusted odds ratio (OR) 0.64 (0.53-0.77), p<0.001] and a lower rate of hospitalization and ICU admission [OR 0.43 (0.28-0.64) p<0.001 and OR 0.51 (0.41-0.64), p<0.001 respectively]. Those with blood eosinophils ≥200 cells/μL, both with and without asthma, had lower mortality. CONCLUSION: Patients with asthma may be at a reduced risk of poor outcomes from COVID-19 infection. Eosinophilia, both in those with and without asthma, may be associated with reduced mortality risk. Since the emergence of a novel coronavirus (SARS-CoV-2), in Wuhan, China, in 2 December 2019, comorbidities such as hypertension, diabetes mellitus, chronic 3 obstructive pulmonary disease (COPD), and tobacco use have been associated with 4 increased severity of COVID-19 infection [1] [2] [3] . Early data from China described a low 5 prevalence of asthma in hospitalized patients, suggesting that underlying asthma was 6 not a risk factor for poor outcomes due to . Other cohort studies 7 assessing asthma as a risk factor for worse outcomes have shown conflicting results, 8 with some reports suggesting increased risk particularly for more severe asthma, and 9 others suggesting asthma may not be a risk factor for worse outcomes [6] [7] [8] [9] [10] [11] . 10 Our current understanding of asthma's pathophysiology is focused on two 11 primary immunological pathways, or endotypes, that underlie the disease. These two 12 endotypes include one characterized by airway eosinophilia and type 2 inflammation, 13 and the other without significant eosinophilia or type 2 inflammation with either 14 neutrophilic inflammation or pauci-inflammatory disease [12] [13] [14] [15] . Peripheral blood 15 eosinophil counts can be used to identify these endotypes and are increasingly used to 16 inform asthma treatment [12, 16] . Eosinophils are potent proinflammatory cells [17] 17 and function as regulatory cells involved in protective immunity, including antiviral 18 responses. Patients with eosinophilic asthma are at an increased risk of viral-induced 19 asthma exacerbations and may have a reduced innate response against respiratory 20 viruses [18 -19] . Eosinophils, however, may also promote protective responses against 21 respiratory viruses [20] . It is unclear if eosinophilic inflammation in asthma is 22 protective or increases the risk of poor COVID-19 infection outcomes. 23 This study's primary aim was to assess the outcomes of patients presenting to 24 the Mount Sinai Health System with a diagnosis of asthma and COVID-19 infections. This 25 study's secondary objective was to determine if peripheral blood eosinophil levels were 26 associated with outcomes in hospitalized patients with COVID-19 infection, both with 27 and without asthma. We hypothesized that asthma did not increase the risk of mortality. In addition, several serum lab markers (i.e. C-reactive protein, and d-dimer) 84 have been identified to be associated with increased mortality; however, the precise No missing variables were observed for patient-related, therapy-related, and 95 outcomes-related variables. Laboratory variables were complete, except for ferritin, IL-96 6, and procalcitonin (all missing variables were less than 3%). To test whether missing 97 data could introduce bias into the study, we made the assumption that data were not 98 missing at random and applied the multivariate imputation method. Overall, 20 imputed 99 data sets were constructed using information from all covariates used in the regression 100 model. Results with and without missing information were not meaningfully different. Thus, results without imputation are reported. Overall, the study population comprised 10,523 patients, of whom 4.47% 105 (n=468) were found to have a diagnosis of asthma. The mean age of the population was 106 58.4 years and was similar between those with and without asthma (TABLE 1) In this study of 10,523 patients diagnosed with COVID-19, including 5123 173 patients managed as outpatients and 4902 patients requiring hospitalization, asthma 174 diagnosis was associated with lower mortality rate, lower hospitalization rate, and 175 lower ICU admission rate than those without asthma when adjusting for comorbidities and concurrent therapies. Moreover, we identified better outcomes associated with 177 absolute eosinophil counts greater than or equal to 200 cells/uL in those with and 178 without asthma. 179 We observed that 468 total study patients had a diagnosis of asthma (4.4%), and 180 asthma was present in 4.8% of hospitalized patients, which is the same prevalence However as described in Table 1 many of the other publications relating to COVID-19 291 and asthma have relied on EMR diagnosis. Furthermore, we were unable to analyse the 292 blood eosinophils as a categorical variable due to the manner of lab reporting which 293 reports values to the nearest hundred. Secondly, the higher rate of COPD and smokers in 294 our asthma group raises suspicion for misdiagnosis of COPD as asthma. Since COPD is 295 amongst the most common comorbidities in patients with fatal COVID-19 disease, we 296 account for this bias by adjusting for smoking and COPD in our multivariate analysis. Thirdly, we cannot exclude that some patients discharged after diagnosis for outpatient 298 treatment of COVID-19 could potentially have been readmitted to non-Mount Sinai 299 system hospitals. We do not have data on atopic status of patients or other measures of 300 type 2 inflammation as previously discussed. We also cannot rule out that patients, 301 especially those with asthma, were treated with oral corticosteroids before hospital 302 admission, impacting outcome and eosinophil grouping. Lastly, this is a retrospective 303 study that is potentially vulnerable to uncontrolled confounders that we did not 304 J o u r n a l P r e -p r o o f 11 identify. While we find a reduced risk of poor outcome overall associated with an 305 asthma diagnosis, we did not account for asthma severity, which has previously been 306 associated with a worse outcome [54] . Charlson comorbidity index, chronic obstructive pulmonary disease (COPD), C-reactive protein (>150), Clinical Characteristics of Coronavirus Disease 2019 in China Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients 319 Hospitalized With COVID-19 in the New York City Area Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With 321 Pneumonia in Wuhan, China Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory Coronavirus Disease 2019 -COVID-NET, 14 States Clinical Characteristics of Covid-19 in Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region Measures of gene expression in sputum cells can identify TH2-high and TH2-low 334 subtypes of asthma Factors associated with COVID-19-related death using OpenSAFELY The Impact of Asthma on Mortality in Patients With COVID-19 Phenotypes and endotypes of adult asthma: Moving toward precision medicine Clinical and inflammatory characteristics of the European U-BIOPRED adult severe 344 asthma cohort T-helper Type 2-driven Inflammation Defines Major Subphenotypes of Asthma External validation of blood eosinophils, FENOand serum periostin as surrogates for 348 sputum eosinophils in asthma Severe Eosinophilic Asthma High fractional exhaled nitric oxide and sputum eosinophils are associated with an 351 increased risk of future virus-induced exacerbations: A prospective cohort study Viral infections in allergy and immunology: 354 How allergic inflammation influences viral infections and illness Eosinophils and Respiratory Viruses. Viral 356 Immunology A new method of classifying prognostic comorbidity in longitudinal 361 studies: Development and validation Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan. A Retrospective Observational Study Clinical predictors of mortality due to COVID-19 based on an analysis of data of 365 150 patients from Wuhan, China Clinical Characteristics, Associated Factors, and Predicting COVID-19 Mortality Risk: A Retrospective 367 Study in Wuhan D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19 Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who 371 require hospitalisation Why asthma might surprisingly protect against poor outcomes in COVID-19 Most Recent Asthma State Data | CDC Prevalence and characterization of asthma in hospitalized and nonhospitalized patients 377 with COVID-19 Asthma prolongs intubation in COVID-19 Importance of accurately identifying disease in studies using electronic health records Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected 383 Pneumonia in Wuhan Comorbidity and its impact on 1590 patients with COVID-19 in China: A nationwide analysis Asthmatic patients in COVID-19 outbreak: Few cases despite many cases Epidemiology, clinical course, and outcomes of critically ill adults with COVID-389 19 in New York City: A prospective cohort study. The Lancet Health Disparities in Asthma Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages 395 in asthmatic subjects Identification of airway mucosal type 2 inflammation by using clinical biomarkers in 398 asthmatic patients External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for 400 sputum eosinophils in asthma SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a 402 Clinically Proven Protease Inhibitor ACE2, TMPRSS2, and furin gene expression in the airways of people with 406 asthma-implications for COVID-19 Type 2 and interferon inflammation strongly regulate SARS-CoV-2 related gene expression 408 in the airway epithelium Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 412 receptor ACE2 Eosinophil responses during COVID-19 infections and coronavirus 414 vaccination Eosinopenia, an early marker of increased mortality in critically ill medical patients Eosinopenia as a marker of mortality and length of stay in 418 patients admitted with exacerbations of chronic obstructive pulmonary disease Behavior of eosinophil leukocytes in acute inflammation. II. Eosinophil dynamics during acute inflammation Eosinophilia in critically ill COVID-19 patients: a French monocenter retrospective study Association of asthma and its genetic predisposition with the risk of 424 severe COVID-19 Allergic disorders and susceptibility to and severity of COVID-19: A nationwide cohort study COVID-19 Autopsies Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet Importance of accurately identifying disease in studies using electronic health records Finding Asthma: Building a Foundation for Care and Discovery Overdiagnosis of asthma in obese and nonobese adults Coexisting Conditions Hypertension Diabetes CKD COPD OSA Smokers Obese (BMI ≥ 30)